在多发性硬化症中比较ocrelizumab与natalizumab的有效性,安全性和持久性:一个现实世界,多中心,倾向性得分匹配的研究
Elena Barbuti1, Alessia Castiello2, Valeria Pozzilli3
1Department of Human Neurosciences, Sapienza University, Rome, Italy.
概括
在多发性硬化症 (MS) 中,ocrelizumab (OCR) 和natalizumab (NTZ) 在五年内显示出可比的有效性. OCR有更多的不良事件,但治疗持久性类似或更好.
科学领域:
- 神经免疫学 神经免疫学
- 临床神经学 临床神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥克雷利祖马布 (OCR) 和纳塔利祖马布 (NTZ) 是多发性硬化症 (MS) 的关键治疗方法.
- 有限的长期,现实世界的比较数据存在于他们的有效性,安全性和持久性.
- 了解这些因素对于优化MS管理至关重要.
研究的目的:
- 为了比较Ocrelizumab (OCR) 与Natalizumab (NTZ) 在现实世界MS患者队列中的长期临床有效性,安全性和治疗持续性.
- 为管理MS患者的临床医生提供基于证据的见解,使用这些疾病修饰疗法.
主要方法:
- 来自意大利两所大学的复发性和进展性多发性硬化症患者的回顾性分析.
- 在OCR和NTZ组之间匹配倾向分数以平衡基线特征.
- 考克斯回归和后勤回归模型用于评估临床结果和不良事件.
主要成果:
- 在55.9个月的平均随访期间,OCR和NTZ组之间没有复发,MRI活动或确认的残疾进展的显著差异.
- OCR治疗与较高的轻度至中度不良事件发生率有关.
- 与NTZ相比,OCR的治疗持续时间与NTZ相比相当或更高.
结论:
- 奥克雷利祖马布和纳塔利祖马布在现实世界MS管理中表现出可比的长期临床有效性.
- 使用ocrelizumab与更高的不良事件发生率有关,但潜在的治疗持久性更大.
- 这些发现支持MS患者的知情治疗决策.
更多相关视频
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...